Jennifer Welsh on Muck Rack

Jennifer Welsh

  • Freelance Journalist, Writer and Editor, Freelance
Connecticut
As seen in: Medium, MSN, Yahoo Life, Business Insider, HuffPost, The Guardian, Wiley Online Library, Cambridge University Press & Assessment, Memory Studies, ScienceDirect and
Covers:  science, environment, space, health, animals, biology
Freelance science writer & editor. Email: microbelover@gmail.com

Get in touch with Jennifer

Contact Jennifer, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Jennifer Welsh’s Biography

Read Full Bio →

As a young girl, I spent most afternoons in my mother's research lab sorting instruments, eventually growing flasks of cells and testing out compounds that could potentially be used to treat cancer. Our dinner table discussions prominently featured the word "apoptosis" and drove my passion for everything science and tech. I parlayed this love into an undergraduate degree in Biological Sciences from the University of Notre Dame, then into a job running the cell culture and antiviral drug toxicit…

Jennifer Welsh’s Journalist Portfolio

Jennifer Welsh

Jennifer Welsh

A list of all my latest writing for BI.

View article →

Articles

Teclistamab Improves Outcomes in Relapsed Multiple Myeloma

|
By Jennifer Welsh
| University of Miami Miller School of Medicine News
Home  /  News  /  Research and Innovation  /  Cancer By: Jennifer Welsh | May 29, 2026 | 8 min. read | Share Summary On teclistamab, nearly two-thirds of multiple myeloma patients achieved complete remission, and many had no detectable myeloma cells on highly sensitive tests. The practice-changing study supports earlier use of immune-based therapies such as teclistamab for multiple myeloma.
Open in Who Shared View Duplicates (4) Issue with article?

New AI tool may help personalize multiple myeloma treatment

|
By Jennifer Welsh, Sadie Harley, Andrew Zinin 
| Medical Xpress
Micrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0 An artificial intelligence-based tool may help physicians determine which newly diagnosed multiple myeloma patients are most likely to benefit from specific therapies, including immunotherapy and stem cell transplantation.
Open in Who Shared View Duplicates (11) Issue with article?

Genetic clues may reveal which rare solitary fibrous tumors are more aggressive, likely to spread

|
By Jennifer Welsh, Sadie Harley, Andrew Zinin 
| Medical Xpress
Credit: Pixabay/CC0 Public Domain Specific genetic fusion patterns in solitary fibrous tumors may help identify which patients face a higher risk of metastasis, recurrence and more aggressive disease behavior, according to new research that could improve how physicians assess and eventually treat this rare cancer.
Open in Who Shared Issue with article?
See all 841 licensed articles (875 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Jennifer

Contact Jennifer, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified